AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLIANCE PHARMA PLC

AGM Information May 18, 2022

7478_dva_2022-05-18_2482de74-14e3-447f-b6f5-bd1e19601aaf.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 9931L

Alliance Pharma PLC

18 May 2022

For immediate release 18 May 2022

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

The votes were as follows:

RESOLUTION VOTES FOR % VOTES AGAINST % VOTES TOTAL % OF ISC VOTED VOTES WITHHELD
1 Report and Accounts 371,393,469 99.99 30,000 0.01 372,087,366 68.97 663,897
2 Final dividend 372,086,356 100.00 0 0.00 372,087,366 68.97 1,010
3 Re-elect P. Butterfield 371,812,794 99.94 238,118 0.06 372,087,366 68.97 36,454
4 Re-elect D. Cook 304,867,206 91.75 27,427,589 8.25 372,087,366 68.97 39,792,571
5 Re-elect A. Franklin 371,701,797 99.91 346,094 0.09 372,087,366 68.97 39,475
6 Re-elect R. Jones 318,832,469 94.70 17,845,835 5.30 372,087,366 68.97 35,409,062
7 Re-elect J. LeCouilliard 283,289,848 84.14 53,391,477 15.86 372,087,366 68.97 35,406,041
8 Elect K. Neirynck 371,168,677 99.76 882,235 0.24 372,087,366 68.97 36,454
9 Re-appoint Auditor 372,018,741 99.99 38,636 0.01 372,087,366 68.97 29,989
10 Remuneration of Auditor 372,058,198 100.00 2,200 0.00 372,087,366 68.97 26,968
11 Allot shares 314,847,187 84.62 57,236,109 15.38 372,087,366 68.97 4,070
12 Disapply Pre-emption rights 318,400,733 85.57 53,682,363 14.43 372,087,366 68.97 4,270

The number of the Group's shares in issue as at the date of the meeting was 539,461,338 ordinary shares of 1p each.

Please note that each share carries one vote and that a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

Chris Chrysanthou

Head of Legal & Company Secretary

18 May 2022

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168
[email protected]
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
[email protected]
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBKFBQQBKDKPD

Talk to a Data Expert

Have a question? We'll get back to you promptly.